FDA Staff Have Questions Whether Effect Of Merck's Drug Is Clinically Meaningful; FDA Staff Says Assessment Of Efficacy Data For Merck's Drug Gefapixant Showed A Small Reduction In Cough Frequency
Portfolio Pulse from Benzinga Newsdesk
FDA staff have raised questions about the clinical meaningfulness of the efficacy data for Merck's drug Gefapixant, noting only a small reduction in cough frequency according to Reuters citing briefing documents.
November 15, 2023 | 5:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
FDA staff's skepticism about the efficacy of Merck's drug Gefapixant could potentially impact Merck's stock negatively due to concerns over the drug's market potential.
The FDA's assessment is a critical factor in the approval and market success of new drugs. The questioning of Gefapixant's efficacy by FDA staff suggests potential hurdles for approval or market adoption, which could negatively affect investor sentiment and Merck's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 90